EUVIMEDEUVIMED entdecken
Open Access

The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment

Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Kentaro Hara, Keisuke Kazama, Keisuke Komori, Aya Kato, Kazuki Otani, Ayako Tamagawa, Haruhiko Cho, Junya Morita, Shinnosuke Kawahara und 5 weitere

In Vivo · 2024

DOI: 10.21873/invivo.13562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Toru Aoyama und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Fibrinogen. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The albumin to fibrinogen ratio (AFR) has been identified as a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of AFR in esophageal cancer patients who received curative resection. PATIENTS AND METHODS: The present study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters were compared between patients with high and low AFRs. RESULTS: The overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed when using a pretreatment AFR of 1.23. When comparing the patient backgrounds between the high-AFR (AFR ≥12.3) and low-AFR (AFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsFibrinogenHumansMaleFemaleMiddle AgedAgedPrognosisBiomarkers, TumorSerum AlbuminNeoplasm StagingNeoplasm Recurrence, LocalAged, 80 and overAdult

Stichwörter der Autor:innen

Esophageal canceralbuminfibrinogensurvival

Substanzen

FibrinogenBiomarkers, TumorSerum Albumin

Autor:innen und Institutionen

  • Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Department of Surgery, Yokohama City University, Yokohama, Japan; itarum1n1@hotmail.com.
  • Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Zitieren

APA

Aoyama, T., Maezawa, Y., Hashimoto, I., Hara, K., Kazama, K., Komori, K., Kato, A., Otani, K., Tamagawa, A., Cho, H., Morita, J., Kawahara, S., Tanabe, M., Oshima, T., Saito, A., Yukawa, N., & Rino, Y. (2024). The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment. In Vivo. https://doi.org/10.21873/invivo.13562

Vancouver

Aoyama T, Maezawa Y, Hashimoto I, Hara K, Kazama K, Komori K, et al. The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment. In Vivo. 2024. doi:10.21873/invivo.13562

BibTeX
@article{Aoyama2024,
  author = {Aoyama, Toru and Maezawa, Yukio and Hashimoto, Itaru and Hara, Kentaro and Kazama, Keisuke and Komori, Keisuke and Kato, Aya and Otani, Kazuki and Tamagawa, Ayako and Cho, Haruhiko and Morita, Junya and Kawahara, Shinnosuke and Tanabe, Mie and Oshima, Takashi and Saito, Aya and Yukawa, Norio and Rino, Yasushi},
  title = {The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment},
  journal = {In Vivo},
  year = {2024},
  doi = {10.21873/invivo.13562}
}
Kostenlos starten →